FY2017 EPS Estimates for Cardiome Pharma Corp Reduced by Analyst (COM)
Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) – Analysts at Cormark lowered their FY2017 earnings per share estimates for Cardiome Pharma Corp in a research report issued to clients and investors on Wednesday. Cormark analyst D. Novak now expects that the biopharmaceutical company will earn ($0.93) per share for the year, down from their prior estimate of ($0.84).
TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-cardiome-pharma-corp-reduced-by-analyst-com/1472040.html.
Separately, HC Wainwright reiterated a “buy” rating on shares of Cardiome Pharma Corp in a report on Wednesday, May 17th.
Cardiome Pharma Corp (TSE:COM) remained flat at $4.93 on Friday. The company’s stock had a trading volume of 9,300 shares. The stock has a 50-day moving average of $5.59 and a 200-day moving average of $4.71. Cardiome Pharma Corp has a 12-month low of $3.25 and a 12-month high of $6.06. The stock’s market capitalization is $159.93 million.
In other Cardiome Pharma Corp news, insider Justin Renz acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was purchased at an average price of C$3.52 per share, for a total transaction of C$35,200.00.
About Cardiome Pharma Corp
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.